Live feed07:00:00·1158dPRReleasevia QuantisnowTyra Biosciences Expands Development of TYRA-300, an Oral FGFR3 Selective Agent, into AchondroplasiaByQuantisnow·Wall Street's wire, on your screen.TYRA· Tyra Biosciences Inc.Health Care
